International Journal of Molecular Sciences (Aug 2022)

The Link between Gut Microbiota and Hepatic Encephalopathy

  • Sung-Min Won,
  • Ki Kwang Oh,
  • Haripriya Gupta,
  • Raja Ganesan,
  • Satya Priya Sharma,
  • Jin-Ju Jeong,
  • Sang Jun Yoon,
  • Min Kyo Jeong,
  • Byeong Hyun Min,
  • Ji Ye Hyun,
  • Hee Jin Park,
  • Jung A. Eom,
  • Su Been Lee,
  • Min Gi Cha,
  • Goo Hyun Kwon,
  • Mi Ran Choi,
  • Dong Joon Kim,
  • Ki Tae Suk

DOI
https://doi.org/10.3390/ijms23168999
Journal volume & issue
Vol. 23, no. 16
p. 8999

Abstract

Read online

Hepatic encephalopathy (HE) is a serious complication of cirrhosis that causes neuropsychiatric problems, such as cognitive dysfunction and movement disorders. The link between the microbiota and the host plays a key role in the pathogenesis of HE. The link between the gut microbiome and disease can be positively utilized not only in the diagnosis area of HE but also in the treatment area. Probiotics and prebiotics aim to resolve gut dysbiosis and increase beneficial microbial taxa, while fecal microbiota transplantation aims to address gut dysbiosis through transplantation (FMT) of the gut microbiome from healthy donors. Antibiotics, such as rifaximin, aim to improve cognitive function and hyperammonemia by targeting harmful taxa. Current treatment regimens for HE have achieved some success in treatment by targeting the gut microbiota, however, are still accompanied by limitations and problems. A focused approach should be placed on the establishment of personalized trial designs and therapies for the improvement of future care. This narrative review identifies factors negatively influencing the gut–hepatic–brain axis leading to HE in cirrhosis and explores their relationship with the gut microbiome. We also focused on the evaluation of reported clinical studies on the management and improvement of HE patients with a particular focus on microbiome-targeted therapy.

Keywords